Haemonetics
268 hedge funds and large institutions have $4.29B invested in Haemonetics in 2020 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 87 increasing their positions, 107 reducing their positions, and 57 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
52% more call options, than puts
Call options by funds: $13.6M | Put options by funds: $8.95M
0.84% less ownership
Funds ownership: 98.36% → 97.52% (-0.84%)
3% less capital invested
Capital invested by funds: $4.44B → $4.29B (-$151M)
6% less funds holding
Funds holding: 285 → 268 (-17)
19% less repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 107
30% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 57
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$74.3M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$73.2M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$50.7M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$40.9M |
| 5 |
ACA
Anchor Capital Advisors
Boston,
Massachusetts
|
+$40.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JSP
Jackson Square Partners
Larkspur,
California
|
-$206M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$38.1M |
| 3 |
Jane Street
New York
|
-$26.4M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$24M |
| 5 |
Renaissance Technologies
New York
|
-$22.2M |
HAE Hedge Fund Activity: Q3 2020 in Review
268 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q3 2020, worth a combined $4.29B — down 3.4% from $4.44B a quarter earlier.
Sellers outnumbered buyers: 57 funds closed out of HAE and 40 opened new positions — a net loss of 17 holders — while 107 trimmed existing stakes and 87 added.
The largest buyer was Point72 Asset Management, adding an estimated $74.3M. The largest seller was Jackson Square Partners, exiting entirely with an estimated $206M sold.
- 268 institutional investors held Haemonetics (HAE) as of Q3 2020, down from 285 in Q2 2020.
- Funds reported $4.29B of Haemonetics stock for Q3 2020, down 3.4% quarter-over-quarter.
- 40 funds opened new Haemonetics positions in Q3 2020 and 57 closed out, a net change of -17 holders.
- The largest Haemonetics buyer in Q3 2020 was Point72 Asset Management, an estimated $74.3M added.
- The largest Haemonetics seller in Q3 2020 was Jackson Square Partners, an estimated $206M sold.
Based on aggregated 13F filings for Q3 2020.